It is safe and effective to use all inside meniscal repair devices for posteromedial meniscal 'ramp' lesions.

PURPOSE: Recently, it has been recognized that meniscocapsular ('ramp') lesions of the posterior one-third of the medial meniscus frequently occur during injuries causing ACL rupture, and that these lesions are easily missed at arthroscopy. Furthermore, it is clear that these lesions are biomechanically significant, adding to the deficits caused by ACL rupture, and that their repair can reverse this. The efficacy of an all inside repair technique has been questioned by some authors and by those who advocate a suture shuttle technique via an accessory posteromedial portal. The use of Ultra FastFix and FastFix 360 meniscal repair devices to repair posteromedial meniscocapsular separations was investigated in terms of safe deployment and the effectiveness. METHODS: Twenty cadaveric fresh frozen knees were used-ten in each of two groups. A ramp lesion was created using a Beaver knife. The lesion was then repaired with either 4 Ultra FastFix (Smith and Nephew) or 4 FastFix 360 (Smith and Nephew) meniscal repair devices. The knees were put through a standardized loading cycle consisting of 10 Lachman's tests and ten maximum loading manual anterior drawer tests at 90° of flexion. Each knee was then flexed and extended fully ten times. The specimens were sectioned just proximal to the menisci and each suture anchor identified and its position recorded and photographed. RESULTS: In the Ultra FastFix group, a single anchor was found to be in an intra-articular position-a failure rate of 2.5%. In the FastFix 360 group, 5 anchors failed-a 12.5% failure rate. In all cases, the anchors were attached to their suture and so not truly loose within the joint. CONCLUSIONS: This study confirms the safe and effective deployment of an all inside repair device for repair of medial meniscal 'ramp' lesions, and therefore its use is advocated in treating these difficult lesions. Ultra FastFix had the lower failure rate of 2.5%, which the authors believe is acceptable, and makes this device preferable to the FastFix360.

A prospective randomized double-blind trial of the use of intrathecal fentanyl in patients undergoing lumbar spinal surgery.

STUDY DESIGN: A randomized, double-blind controlled study. OBJECTIVE: To assess the efficacy and safety of intrathecal fentanyl in the relief of postoperative pain in patients undergoing lumbar spinal surgery. SUMMARY OF BACKGROUND DATA: Fentanyl has been used as a spinal analgesic in surgery and obstetrics with several studies promoting its efficacy and safety. There is no evidence in the literature about intrathecal fentanyl in lumbar spinal surgery. Previous studies have looked at the use of intrathecal morphine and conclude that it is effective but also associated with respiratory depression. METHODS: Sixty patients undergoing posterior lumbar spine decompression with or without instrumented fusion were randomized to receive either 15 mug of fentanyl intrathecally under direct vision or nothing just before wound closure. After surgery, all patients received intravenous (IV) morphine via patient-controlled analgesia system (PCA) syringe driver. Outcome measures included visual analogue scores (VAS) for pain, time to first bolus of IV morphine PCA, and total amount of morphine PCA used. RESULTS: The patients who received fentanyl demonstrated a significant decrease in their mean pain VAS, an increase in the time to first PCA bolus, and a 41% reduction in the total PCA morphine received. No patients had respiratory compromise requiring treatment. There was no significant difference between the two groups with respect to age, gender, and case mix. CONCLUSION: Intrathecal fentanyl is effective at reducing pain and morphine PCA use after lumbar spinal surgery with minimal respiratory depression.